CD38 Directed Therapies

Jul 20, 2026

Summary SARCLISA ESCENA is the first anticancer treatment approved for delivery via an on-body injector — approved in the US, EU, and UK. It's delivered via CirCLIQ, a hands-free wearable device built on Enable Injections' enFuse platform. Approval was supported by the Phase 3 IRAKLIA trial, showing effic...

Sep 24, 2024

The landscape of multiple myeloma therapies has been revolutionized by the introduction of cutting-edge monoclonal antibodies (mAbs) targeting CD38. Among the standout advancements are DARZALEX (daratumumab) and SARCLISA (isatuximab-irfc), which have emerged as game-changers in the treatment of multiple myeloma. Th...